Results 201 to 210 of about 66,268 (303)
Linagliptin Increases Incretin Levels, Lowers Glucagon, and Improves Glycemic Control in Type 2 Diabetes Mellitus [PDF]
core +1 more source
Cannabinoids and drug–drug pharmacokinetic interactions: Deciphering the risks
The relationship between cannabinoids and mental health has become a major focus of scientific inquiry and public discourse. Cannabinoids are diverse chemical compounds from the Cannabis species that have been explored for their therapeutic applications in treating chronic pain, psychiatric and neurological conditions, such as depression, schizophrenia,
Paraskevi Papakyriakopoulou +2 more
wiley +1 more source
DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes [PDF]
core +1 more source
Exploring the chemical profile and biological property of O. majorana EO. ABSTRACT Diabetes mellitus is a widespread metabolic disorder characterized by impaired glucose regulation. This study investigated the chemical composition and antidiabetic potential of Origanum majorana essential oil (EO) using integrated in vitro, in vivo, and computational ...
Mahmoud Houas +12 more
wiley +1 more source
A Case of Bullous Pemphigoid Triggered by COVID-19 Infection in a Patient Receiving a Dipeptidyl Peptidase-4 Inhibitor. [PDF]
Fukata M +5 more
europepmc +1 more source
MOG antibody‐associated cortical encephalitis (MOG‐CCE) presents a distinct clinical phenotype characterized by seizure‐dominant onset, unilateral cortical lesions, and favorable immunotherapy response, highlighting the diagnostic and prognostic value of antibody profiling in autoimmune cortical encephalitis.
Qing Yin +7 more
wiley +1 more source
Cardiovascular and renal outcomes of sodium-glucose cotransporter-2 versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes post-PCI: a meta-analysis of 14,511 patients. [PDF]
Badran AS +3 more
europepmc +1 more source
With the increasing volume of clinical evidence derived from large‐scale Asian real‐world data (RWD) and the growing interest in its use in regulatory decision‐making, it is important to conduct benchmarking exercises that evaluate whether studies using Asian RWD can generate similar conclusions as randomized controlled trials (RCTs).
Hwa Yeon Ko +15 more
wiley +1 more source

